Alector (ALEC) Competitors $1.87 +0.01 (+0.54%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.87 0.00 (0.00%) As of 02/21/2025 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALEC vs. ANAB, KURA, CRMD, ABUS, PHAR, IMTX, ORIC, RAPP, SEPN, and PGENShould you be buying Alector stock or one of its competitors? The main competitors of Alector include AnaptysBio (ANAB), Kura Oncology (KURA), CorMedix (CRMD), Arbutus Biopharma (ABUS), Pharming Group (PHAR), Immatics (IMTX), ORIC Pharmaceuticals (ORIC), Rapport Therapeutics (RAPP), Septerna (SEPN), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry. Alector vs. AnaptysBio Kura Oncology CorMedix Arbutus Biopharma Pharming Group Immatics ORIC Pharmaceuticals Rapport Therapeutics Septerna Precigen Alector (NASDAQ:ALEC) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, community ranking, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Do institutionals and insiders hold more shares of ALEC or ANAB? 85.8% of Alector shares are held by institutional investors. 9.1% of Alector shares are held by company insiders. Comparatively, 33.7% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ALEC or ANAB more profitable? Alector has a net margin of -257.54% compared to AnaptysBio's net margin of -289.75%. Alector's return on equity of -108.77% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets Alector-257.54% -108.77% -27.03% AnaptysBio -289.75%-287.94%-37.25% Does the MarketBeat Community believe in ALEC or ANAB? AnaptysBio received 217 more outperform votes than Alector when rated by MarketBeat users. Likewise, 66.19% of users gave AnaptysBio an outperform vote while only 61.02% of users gave Alector an outperform vote. CompanyUnderperformOutperformAlectorOutperform Votes15561.02% Underperform Votes9938.98% AnaptysBioOutperform Votes37266.19% Underperform Votes19033.81% Do analysts rate ALEC or ANAB? Alector presently has a consensus price target of $3.75, indicating a potential upside of 100.53%. AnaptysBio has a consensus price target of $36.20, indicating a potential upside of 94.44%. Given Alector's higher possible upside, equities analysts clearly believe Alector is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14AnaptysBio 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.73 Which has better valuation & earnings, ALEC or ANAB? Alector has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlector$97.06M1.89-$130.39M-$1.70-1.10AnaptysBio$17.16M33.02-$163.62M-$6.08-3.06 Does the media refer more to ALEC or ANAB? In the previous week, AnaptysBio had 5 more articles in the media than Alector. MarketBeat recorded 8 mentions for AnaptysBio and 3 mentions for Alector. Alector's average media sentiment score of 0.20 beat AnaptysBio's score of 0.13 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AnaptysBio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAlector beats AnaptysBio on 9 of the 17 factors compared between the two stocks. Get Alector News Delivered to You Automatically Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALEC vs. The Competition Export to ExcelMetricAlectorBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$182.15M$3.12B$5.85B$9.15BDividend YieldN/A1.56%4.76%3.85%P/E RatioN/A10.3116.5114.19Price / Sales1.89327.11450.0276.60Price / CashN/A168.8538.0134.95Price / Book1.333.687.644.63Net Income-$130.39M-$71.72M$3.18B$245.69M7 Day Performance10.00%-2.46%-1.95%-2.68%1 Month Performance5.06%-0.25%-0.23%-2.16%1 Year Performance-71.10%-12.31%16.69%12.90% Alector Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALECAlector4.0749 of 5 stars$1.87+0.5%$3.75+100.5%-69.9%$182.15M$97.06M-1.10270Upcoming EarningsANABAnaptysBio3.77 of 5 stars$21.22+10.0%$37.45+76.5%-27.0%$645.73M$17.16M-3.49100High Trading VolumeKURAKura Oncology4.4041 of 5 stars$8.28flat$27.13+227.6%-58.7%$643.85MN/A-3.51130CRMDCorMedix1.325 of 5 stars$10.48+0.4%$15.67+49.5%+211.7%$635.90M$12.26M-12.9430News CoveragePositive NewsABUSArbutus Biopharma1.6623 of 5 stars$3.29-0.3%$5.50+67.2%+18.9%$623.42M$18.14M-7.6590PHARPharming Group2.9186 of 5 stars$9.13+3.2%$27.00+195.7%-19.7%$621.19M$285.75M-35.12280Positive NewsGap UpIMTXImmatics1.6069 of 5 stars$5.05-0.8%$16.67+230.0%-61.7%$602.77M$58.44M-7.65260ORICORIC Pharmaceuticals4.5393 of 5 stars$8.36+1.1%$18.71+123.9%-25.6%$589.97MN/A-4.6480Earnings ReportAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeRAPPRapport Therapeutics1.8127 of 5 stars$15.90+0.8%$35.00+120.1%N/A$581.62MN/A0.00N/AUpcoming EarningsSEPNSepterna2.177 of 5 stars$12.96+12.2%$43.67+236.9%N/A$575.42MN/A0.00N/AAnalyst DowngradeAnalyst RevisionNews CoverageGap UpPGENPrecigen3.9524 of 5 stars$1.96-1.0%$7.00+257.1%+34.5%$574.03M$6.22M-3.56190Gap Up Related Companies and Tools Related Companies AnaptysBio Alternatives Kura Oncology Alternatives CorMedix Alternatives Arbutus Biopharma Alternatives Pharming Group Alternatives Immatics Alternatives ORIC Pharmaceuticals Alternatives Rapport Therapeutics Alternatives Septerna Alternatives Precigen Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALEC) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALEC Stock Alerts